HK1232163A1 - 用於抑制α- 抗胰蛋白酶基因表達的組合物及方法 - Google Patents
用於抑制α- 抗胰蛋白酶基因表達的組合物及方法Info
- Publication number
- HK1232163A1 HK1232163A1 HK17106007.9A HK17106007A HK1232163A1 HK 1232163 A1 HK1232163 A1 HK 1232163A1 HK 17106007 A HK17106007 A HK 17106007A HK 1232163 A1 HK1232163 A1 HK 1232163A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antitrypsin
- alpha
- compositions
- methods
- gene expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462013288P | 2014-06-17 | 2014-06-17 | |
PCT/US2015/035976 WO2015195628A2 (en) | 2014-06-17 | 2015-06-16 | Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1232163A1 true HK1232163A1 (zh) | 2018-01-05 |
Family
ID=54835647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK17106007.9A HK1232163A1 (zh) | 2014-06-17 | 2017-06-16 | 用於抑制α- 抗胰蛋白酶基因表達的組合物及方法 |
Country Status (13)
Country | Link |
---|---|
US (4) | US10006025B2 (zh) |
EP (1) | EP3157541A4 (zh) |
CN (2) | CN113444725A (zh) |
AR (1) | AR100840A1 (zh) |
AU (2) | AU2015277376B2 (zh) |
BR (1) | BR112016029781A2 (zh) |
CA (2) | CA3219720A1 (zh) |
EA (1) | EA201692318A1 (zh) |
HK (1) | HK1232163A1 (zh) |
IL (1) | IL249597A0 (zh) |
MX (3) | MX2016015870A (zh) |
TW (1) | TW201620526A (zh) |
WO (1) | WO2015195628A2 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011091065A2 (en) | 2010-01-19 | 2011-07-28 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
AU2014292926B2 (en) | 2013-07-25 | 2020-03-05 | Exicure Operating Company | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
PL3164113T3 (pl) | 2014-06-04 | 2019-09-30 | Exicure, Inc. | Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych |
TW201620526A (zh) * | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α-1抗胰蛋白酶基因表現之組合物及方法 |
KR20170063949A (ko) | 2014-10-06 | 2017-06-08 | 엑시큐어, 인크. | 항-tnf 화합물 |
ES2858403T3 (es) * | 2014-12-15 | 2021-09-30 | Dicerna Pharmaceuticals Inc | Acidos nucleicos de doble hebra modificados por ligando |
WO2017139616A1 (en) * | 2016-02-10 | 2017-08-17 | Arrowhead Pharmaceuticals, Inc. | Methods of treatment for alpha-1 antitrypsin deficiency |
KR20230048446A (ko) | 2016-03-07 | 2023-04-11 | 애로우헤드 파마슈티컬스 인코포레이티드 | 치료용 화합물을 위한 표적화 리간드 |
JP7186094B2 (ja) | 2016-05-06 | 2022-12-08 | イグジキュア オペレーティング カンパニー | インターロイキン17受容体mRNAの特異的ノックダウンのためのアンチセンスオリゴヌクレオチド(ASO)を提示するリポソーム系球状核酸(SNA)構築物 |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
KR20230115344A (ko) | 2016-09-02 | 2023-08-02 | 애로우헤드 파마슈티컬스 인코포레이티드 | 표적화 리간드 |
WO2018102397A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
UY37565A (es) * | 2017-01-10 | 2018-07-31 | Arrowhead Pharmaceuticals Inc | Agentes de iarn alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y métodos de uso |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
SE540888C2 (en) * | 2017-06-19 | 2018-12-11 | Hepgene Medical Ab | Novel nucleic acid molecules and their use in therapy |
JP2022535127A (ja) * | 2019-06-06 | 2022-08-04 | アローヘッド ファーマシューティカルズ インコーポレイテッド | アルファ-1アンチトリプシン欠乏症(aatd)の治療法 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
EP0366685B1 (en) | 1987-06-24 | 1994-10-19 | Howard Florey Institute Of Experimental Physiology And Medicine | Nucleoside derivatives |
IE61148B1 (en) * | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
DE69034150T2 (de) | 1989-10-24 | 2005-08-25 | Isis Pharmaceuticals, Inc., Carlsbad | 2'-Modifizierte Oligonukleotide |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5212295A (en) | 1990-01-11 | 1993-05-18 | Isis Pharmaceuticals | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
JP2823959B2 (ja) | 1991-10-24 | 1998-11-11 | アイシス・ファーマシューティカルス・インコーポレーテッド | 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド |
US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
NZ503765A (en) | 1997-09-12 | 2002-04-26 | Exiqon As | Bi-cyclic and tri-cyclic nucleotide analogues |
FR2774379B1 (fr) | 1998-01-30 | 2002-03-29 | Groupe Limagrain Holding | Procede de production, par des cellules vegetales, d'alpha 1-antitrypsine et de ses variantes, et produits contenant l'alpha-antitrypsine ainsi obtenue |
US6271358B1 (en) | 1998-07-27 | 2001-08-07 | Isis Pharmaceuticals, Inc. | RNA targeted 2′-modified oligonucleotides that are conformationally preorganized |
ID30093A (id) | 1999-02-12 | 2001-11-01 | Sankyo Co | Analog-analog nukleosida dan oligonukleotida baru |
MXPA01009073A (es) | 1999-03-10 | 2002-05-06 | Phogen Ltd | Suministro de acidos nucleicos y proteinas a las celulas. |
US20050137153A1 (en) * | 2002-02-20 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA) |
AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
ATE443765T1 (de) | 2003-03-21 | 2009-10-15 | Santaris Pharma As | Analoga kurzer interferierender rna (sirna) |
AU2005222965B8 (en) | 2004-03-15 | 2010-07-01 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
WO2008022309A2 (en) | 2006-08-18 | 2008-02-21 | F. Hoffmann-La Roche Ag | Polyconjugates for in vivo delivery of polynucleotides |
CA2687850C (en) * | 2007-05-22 | 2017-11-21 | Mdrna, Inc. | Oligomers for therapeutics |
CA2718765A1 (en) * | 2008-03-20 | 2009-09-24 | Quark Pharmaceuticals, Inc. | Novel sirna compounds for inhibiting rtp801 |
CA3151965A1 (en) | 2008-12-18 | 2010-07-15 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
ES2562817T3 (es) | 2010-02-24 | 2016-03-08 | Arrowhead Research Corporation | Composiciones para el suministro dirigido de ARNip |
JP6053684B2 (ja) * | 2010-09-07 | 2016-12-27 | インテグレイテツド・デイー・エヌ・エイ・テクノロジーズ・インコーポレイテツド | アンチセンス化合物の修飾 |
US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
CA2822161C (en) | 2010-12-29 | 2018-05-29 | Philipp Hadwiger | Small molecule conjugates for intracellular delivery of nucleic acids |
EP2723390B1 (en) | 2011-06-23 | 2017-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
WO2013142514A1 (en) | 2012-03-19 | 2013-09-26 | Isis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
UY35582A (es) | 2013-05-22 | 2014-10-31 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO |
WO2014197524A2 (en) | 2013-06-06 | 2014-12-11 | Serpin Pharma, Llc | Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies |
PT3444350T (pt) * | 2013-07-03 | 2022-02-04 | Dicerna Pharmaceuticals Inc | Métodos e composições para a inibição específica de alfa-1 antitripsina através de arn de cadeia dupla |
TW201620526A (zh) * | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α-1抗胰蛋白酶基因表現之組合物及方法 |
-
2015
- 2015-06-10 TW TW104118826A patent/TW201620526A/zh unknown
- 2015-06-15 AR ARP150101897A patent/AR100840A1/es unknown
- 2015-06-16 CN CN202110660130.8A patent/CN113444725A/zh active Pending
- 2015-06-16 WO PCT/US2015/035976 patent/WO2015195628A2/en active Application Filing
- 2015-06-16 BR BR112016029781A patent/BR112016029781A2/pt not_active IP Right Cessation
- 2015-06-16 MX MX2016015870A patent/MX2016015870A/es active IP Right Grant
- 2015-06-16 US US14/740,307 patent/US10006025B2/en active Active
- 2015-06-16 CA CA3219720A patent/CA3219720A1/en active Pending
- 2015-06-16 EP EP15809171.0A patent/EP3157541A4/en active Pending
- 2015-06-16 EA EA201692318A patent/EA201692318A1/ru unknown
- 2015-06-16 CN CN201580032508.2A patent/CN106535917B/zh active Active
- 2015-06-16 CA CA2951700A patent/CA2951700C/en active Active
- 2015-06-16 AU AU2015277376A patent/AU2015277376B2/en active Active
-
2016
- 2016-12-01 MX MX2023003672A patent/MX2023003672A/es unknown
- 2016-12-01 MX MX2020010524A patent/MX2020010524A/es unknown
- 2016-12-15 IL IL249597A patent/IL249597A0/en unknown
-
2017
- 2017-06-16 HK HK17106007.9A patent/HK1232163A1/zh unknown
-
2018
- 2018-05-25 US US15/990,330 patent/US20180258430A1/en not_active Abandoned
-
2019
- 2019-05-31 US US16/428,431 patent/US11384355B2/en active Active
-
2021
- 2021-06-28 AU AU2021204399A patent/AU2021204399A1/en active Pending
-
2022
- 2022-06-08 US US17/834,988 patent/US20230002768A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2015195628A3 (en) | 2016-02-18 |
WO2015195628A2 (en) | 2015-12-23 |
MX2020010524A (es) | 2020-11-06 |
US10006025B2 (en) | 2018-06-26 |
AU2015277376A1 (en) | 2016-12-08 |
AU2021204399A1 (en) | 2021-07-22 |
US20190284558A1 (en) | 2019-09-19 |
US20150361427A1 (en) | 2015-12-17 |
CA2951700A1 (en) | 2015-12-23 |
IL249597A0 (en) | 2017-02-28 |
BR112016029781A2 (pt) | 2017-10-31 |
CN113444725A (zh) | 2021-09-28 |
CA3219720A1 (en) | 2015-12-23 |
EA201692318A1 (ru) | 2017-06-30 |
TW201620526A (zh) | 2016-06-16 |
MX2016015870A (es) | 2017-04-27 |
AR100840A1 (es) | 2016-11-02 |
CN106535917B (zh) | 2021-07-06 |
US11384355B2 (en) | 2022-07-12 |
EP3157541A4 (en) | 2018-04-04 |
CA2951700C (en) | 2024-01-02 |
AU2015277376B2 (en) | 2021-04-01 |
EP3157541A2 (en) | 2017-04-26 |
US20230002768A1 (en) | 2023-01-05 |
US20180258430A1 (en) | 2018-09-13 |
MX2023003672A (es) | 2023-04-18 |
CN106535917A (zh) | 2017-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290566A (en) | Preparations and methods for preventing lipoprotein A gene expression | |
HK1232163A1 (zh) | 用於抑制α- 抗胰蛋白酶基因表達的組合物及方法 | |
HRP20181630T1 (hr) | Postupci i kompoziti za ciljne genetske modifikacije i načini korištenja | |
IL273875A (en) | Methods and compounds for inhibiting expression of LDHA | |
IL254518A0 (en) | Preparations and methods for suppressing the expression of the factor xii gene | |
HK1252852A1 (zh) | 阻止HIF2α基因表達的組合物及方法 | |
IL282747A (en) | Preparations and methods for inhibiting expression of the ALAS1 gene | |
EP3105327A4 (en) | Compositions and methods of using microrna inhibitors | |
EP3237619B8 (en) | Compositions and methods for inhibiting expression of adamts-5 and adam17 |